Mark Velleca

With a potential FDA approval looming, G1 Therapeutics taps ex-GSK US president Jack Bailey as new CEO
Endpoints
Thu, 10/1/20 - 11:04 pm
G1 Therapeutics
GSK
John Bailey
Mark Velleca